Repair Biotechnologies

Executive Summary

Repair Biotechnologies is a preclinical-stage biotechnology company pioneering a novel Cholesterol Degrading Platform (CDP) to address the root cause of atherosclerosis. Founded in 2018 and headquartered in Ithaca, NY, the company is engineering human cells to break down excess cholesterol, thereby reversing atherosclerotic plaque—a paradigm shift from managing symptoms to curing cardiovascular disease. Its lead program aims for rapid plaque regression, potentially offering a first-in-class therapy for a massive global patient population. The CDP technology leverages synthetic biology to express cholesterol-degrading enzymes directly in cells, enabling localized clearance of lipid deposits. This approach could eliminate the need for lifelong statin therapy and reduce the residual risk of cardiovascular events. Repair Biotechnologies is currently in the preclinical phase, completing IND-enabling studies to support an initial Investigational New Drug (IND) filing. If successful, the platform could be expanded to other cholesterol-driven pathologies. The company operates with a lean team and has not disclosed funding details, suggesting a strategic focus on achieving key milestones before seeking larger financing rounds. The growing burden of cardiovascular disease and the lack of curative treatments highlight the high unmet need that Repair aims to fill. As the company advances toward clinical trials, its unique mechanism of action and potential for disease reversal position it as a compelling player in the cell and gene therapy space.

Upcoming Catalysts (preview)

• Q3 2026Initiation of IND-enabling toxicology studies80% success
• H1 2027First-in-human clinical trial start (Phase I)40% success
• H2 2026Partnership or licensing deal with a larger pharmaceutical company30% success